Moderna recently reported positive results from its phase 3 trial of a combined COVID and influenza vaccine, mRNA-1083. The trial involved over 8,000 participants across two age groups, showing a robust immune response against COVID and influenza strains compared to separate vaccines. Safety profiles were similar between the combined and co-administered vaccines. If approved, this vaccine could streamline immunization efforts, reduce costs, and potentially improve uptake, especially in underserved regions.